Thermo Fisher Scientific Inc. TMO
NYSE
| 09/26/2026 | 06/27/2026 | 03/28/2026 | 12/31/2025 | 09/27/2025 | |
|---|---|---|---|---|---|
| Revenue | 12.14B | 11.99B | 11.01B | 12.22B | 11.12B |
| Total Other Revenue | -- | -- | -- | 0.00 | -- |
| Total Revenue | 12.14B | 11.99B | 11.01B | 12.22B | 11.12B |
| Cost of Revenue | 7.00B | 7.08B | 6.56B | 7.17B | 6.53B |
| Gross Profit | 5.14B | 4.91B | 4.44B | 5.04B | 4.59B |
| SG&A Expenses | 2.34B | 2.30B | 2.14B | 2.24B | 2.10B |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | 1.00M | -135.00M | -- |
| Total Operating Expenses | 9.69B | 9.75B | 9.04B | 9.63B | 8.97B |
| Operating Income | 2.45B | 2.25B | 1.97B | 2.59B | 2.15B |
| Income Before Tax | 2.08B | 1.91B | 1.73B | 2.12B | 1.83B |
| Income Tax Expenses | 352.00M | 167.00M | 70.00M | 153.00M | 207.00M |
| Earnings from Continuing Operations | 1.73B | 1.74B | 1.66B | 1.97B | 1.62B |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -6.00M | -5.00M | -5.00M | -6.00M | -5.00M |
| Net Income | 1.72B | 1.74B | 1.65B | 1.96B | 1.62B |
| EBIT | 2.45B | 2.25B | 1.97B | 2.59B | 2.15B |
| EBITDA | 3.28B | 3.07B | 2.70B | 3.31B | 2.81B |
| EPS Basic | 4.65 | 4.68 | 4.44 | 5.22 | 4.28 |
| Normalized Basic EPS | 3.83 | 3.43 | 3.06 | 4.04 | 3.34 |
| EPS Diluted | 4.64 | 4.68 | 4.43 | 5.19 | 4.27 |
| Normalized Diluted EPS | 3.82 | 3.43 | 3.06 | 4.03 | 3.34 |
| Average Basic Shares Outstanding | 370.00M | 371.00M | 372.00M | 376.00M | 378.00M |
| Average Diluted Shares Outstanding | 371.00M | 371.00M | 373.00M | 377.00M | 378.00M |
| Dividend Per Share | 0.47 | 0.47 | 0.47 | 0.43 | 0.43 |
| Payout Ratio | 10.11% | 10.08% | 9.81% | 8.25% | 10.09% |